Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
FibroGen Inc (NASDAQ: FGEN) closed the day trading at $0.46 down -2.61% from the previous closing price of $0.48. In other words, the price has decreased by -$2.61 from its previous closing price. On the day, 0.61 million shares were traded. FGEN stock price reached its highest trading level at $0.4827 during the session, while it also had its lowest trading level at $0.4517.
Ratios:
For a better understanding of FGEN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 08, 2023, Downgraded its rating to Underperform and sets its target price to $2 from $4 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 12 ’24 when Adib Deyaa bought 22,123 shares for $1.17 per share. The transaction valued at 25,884 led to the insider holds 82,123 shares of the business.
Wettig Thane bought 50,000 shares of FGEN for $95,470 on Mar 07 ’24. The CEO now owns 470,178 shares after completing the transaction at $1.91 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FGEN now has a Market Capitalization of 46676664 and an Enterprise Value of 103849944. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26. Its current Enterprise Value per Revenue stands at 0.597 whereas that against EBITDA is -0.626.
Stock Price History:
The Beta on a monthly basis for FGEN is 0.80, which has changed by -0.78064513 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, FGEN has reached a high of $2.93, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is -0.99%, while the 200-Day Moving Average is calculated to be -29.78%.
Shares Statistics:
Over the past 3-months, FGEN traded about 1.31M shares per day on average, while over the past 10 days, FGEN traded about 779850 shares per day. A total of 100.77M shares are outstanding, with a floating share count of 93.69M. Insiders hold about 7.02% of the company’s shares, while institutions hold 45.47% stake in the company. Shares short for FGEN as of 1730332800 were 4324077 with a Short Ratio of 2.35, compared to 1727654400 on 4544637. Therefore, it implies a Short% of Shares Outstanding of 4324077 and a Short% of Float of 5.07.
Earnings Estimates
The stock of FibroGen Inc (FGEN) is currently in the spotlight, with 1.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.86 and -$0.86 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is -$0.38, with 1.0 analysts recommending between -$0.38 and -$0.38.
Revenue Estimates
2 analysts predict $24.91M in revenue for the current quarter. It ranges from a high estimate of $25.82M to a low estimate of $24M. As of the current estimate, FibroGen Inc’s year-ago sales were $27.14M
A total of 2 analysts have provided revenue estimates for FGEN’s current fiscal year. The highest revenue estimate was $178.7M, while the lowest revenue estimate was $177M, resulting in an average revenue estimate of $177.85M. In the same quarter a year ago, actual revenue was $147.75MBased on 2 analysts’ estimates, the company’s revenue will be $166.15M in the next fiscal year. The high estimate is $187.3M and the low estimate is $145M.
